Assistance Options For Your Eligible Patients

Several options are available to help eligible patients with the out-of-pocket (OOP) costs of Avastin.

Find the right patient assistance option for your patient using the Patient Assistance Tool.

Is your patient insured?
Does the patient's insurance cover his or her Genentech medicine?
Does your patient have commercial insurance?
What does this mean?
Has your patient already been referred to the Genentech Oncology Co-pay Assistance Program and is either ineligible or no longer receiving assistance?
Has your patient already been referred to an independent co-pay assistance foundation and is either ineligible or no longer receiving assistance?
Is the patient 18 years of age or older?

Your Patient Might Qualify for a Referral to the Genentech Oncology Co-pay Assistance Program

If eligible commercially insured patients need assistance with their out-of-pocket costs, Avastin Access Solutions can refer them to the Genentech Oncology Co-pay Assistance Program.*

Learn More

*Eligibility criteria apply. Not valid for patients using federal or state government programs to pay for their medications and or administration of their Genentech medication. Patient must be taking the Genentech medication for an FDA-approved indication. See full Terms and Conditions at CopayAssistanceNow.com.

Your Patient Might Qualify for a Referral to an Independent Co-pay Assistance Foundation

For eligible patients with commercial or public health insurance, Avastin Access Solutions offers referrals to independent co-pay assistance foundations.*

Learn More

*Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Avastin Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s endorsement or financial support. There may be other foundations to support the patient's disease state.

Your Patient Might Qualify for a Referral to the Genentech Patient Foundation

The Genentech Patient Foundation provides free Genentech medicine to people who don't have insurance coverage or who have financial concerns and to people who meet certain income criteria.*

Learn More

*To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine should try to pursue other forms of financial assistance, if available, and meet certain income requirements. Uninsured patients and insured patients without coverage for their medicine must meet a different set of income requirements.

Does your patient have commercial insurance?

Genentech Oncology Access Solutions for Avastin can refer eligible patients to the Genentech Oncology Co-pay Program* for help with the OOP cost associated with Avastin.

Learn more

Does your patient have insurance?

If eligible publicly or commercially insured patients have difficulty paying for their co-pay, co-insurance, or other OOP costs, Genentech Oncology Access Solutions can refer them to an independent co-pay assistance foundation supporting their disease state.^†

Learn more

Does your patient have no insurance or have financial concerns?

The Genentech Patient Foundation helps people affected by serious medical conditions get the Avastin they have been prescribed. People who do not have health insurance, who have health insurance that does not cover their Avastin, or who can’t afford their OOP costs may get free medicine.^‡

Learn more

*This Genentech Oncology Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid, or any other federal or state government program to pay for their medications are not eligible.

Under the Program, the patient will pay a co-pay. After reaching the maximum Program benefit, the patient will be responsible for all out-of-pocket costs.

All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. This Program is void where prohibited by law. Genentech reserves the right to rescind, revoke, or amend the Program without notice at any time. Additional eligibility criteria apply. See full terms and conditions at https://www.copayassistancenow.com/#/avastin/co-paycard.

^†Genentech and Avastin do not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech Oncology Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s endorsement or financial support. There may be other foundations to support the patient’s disease state.
^‡To be eligible for free Avastin from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Genentech Oncology Co-pay Program and support from independent co-pay assistance foundations) and must meet certain financial criteria. Uninsured patients and insured patients without coverage for their medicine must meet different financial criteria.

Serious adverse reactions (Warnings and Precautions)

Serious and sometimes fatal adverse reactions with increased incidence in the Avastin-treated arm vs chemotherapy arm included:

Gastrointestinal (GI) perforation ranged from 0.3% to 3% of patients across clinical studies
Non-GI fistulae (<1% to 1.8%, highest in patients with cervical cancer)
Arterial thromboembolic events (Grade ≥3, 5%, highest in patients with GBM)
The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in Avastin-treated patients
Hemorrhage (Grade 3–5) ranged from 0.4% to 7% of patients across clinical studies
Renal injury and proteinuria
- Grade 3–4 proteinuria ranged from 0.7% to 7% in clinical studies
- Nephrotic syndrome (<1%)

Additional serious adverse reactions with increased incidence in the Avastin-treated arm vs chemotherapy arm included:

Venous thromboembolism (Grade ≥3, 11% seen in GOG-0240)
Hypertension (Grade 3–4, 5%–18%)
Posterior reversible encephalopathy syndrome (PRES) (<0.5%)
Congestive heart failure (CHF): Grade ≥3 left ventricular dysfunction (1%)

Infusion-related reactions with the first dose of Avastin occurred in <3% of patients, and severe reactions occurred in 0.4% of patients

Avoid use in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction

Inform females of reproductive potential of the risk of ovarian failure prior to initiating treatment with Avastin

An evaluation for the presence of varices is recommended within 6 months of initiation of Avastin in patients with HCC

Pregnancy warning

Based on the mechanism of action and animal studies, Avastin may cause fetal harm

Advise female patients that Avastin may cause fetal harm, and to inform their healthcare provider of a known or suspected pregnancy

Advise females of reproductive potential to use effective contraception during treatment with Avastin and for 6 months after the last dose of Avastin

Advise nursing women not to breastfeed during treatment with Avastin and for 6 months following their last dose of treatment

Avastin may impair fertility

Most common adverse reactions

Across studies, the most common adverse reactions observed in Avastin patients at a rate >10% were:

Epistaxis
Headache
Hypertension
Rhinitis
Proteinuria
Taste alteration
Dry skin
Hemorrhage
Lacrimation disorder
Back pain
Exfoliative dermatitis

Across all studies, Avastin was discontinued in 8% to 22% of patients because of adverse reactions

Assistance Options For Your Eligible Patients

Find the right patient assistance option for your patient using the Patient Assistance Tool.

Patient Assistance
Tool

Does your patient have commercial insurance?

Does your patient have insurance?

Does your patient have no insurance or have financial concerns?

What is Genentech Oncology Access Solutions?

How can I find what options are available for my patient?

How can I enroll my patients?

Once enrolled in a program, how long will my patient keep receiving assistance?

What if I have questions about your programs?

Important Safety Information & Indications

Serious adverse reactions (Warnings and Precautions)

Pregnancy warning

Most common adverse reactions

Indication-specific adverse reactions

Indications

Assistance Options For Your Eligible Patients

Find the right patient assistance option for your patient using the Patient Assistance Tool.

Patient AssistanceTool

Does your patient have commercial insurance?

Does your patient have insurance?

Does your patient have no insurance or have financial concerns?

Important Safety Information & Indications

Serious adverse reactions (Warnings and Precautions)

Pregnancy warning

Most common adverse reactions

Indication-specific adverse reactions

Indications

Patient Assistance
Tool